ArticleMethods in molecular biology (Clifton, N.J.)2026
Generation of Bispecific Antibodies Using FAST-Ig™.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust generation of bispecific antibodies (BsAbs) in single-cell expression systems is essential for basic research and industrial manufacturing. However, the low yield of BsAbs and complicated downstream processing caused by the random assembly of heavy chains (HCs) and light chains (LCs) have limited the use of BsAbs in clinical and preclinical studies. Major technological improvements have been established to address the issues of HC homodimerization and noncognate HC and LC pairing. Nevertheless, current existing methods need to determine common light chains, extensively engineer each Fv portion or perform labor-intensive biochemical processing making downstream processing highly challenging. Here, we describe an engineering technology for preferential cognate HC/LC and HC/HC pairing called four-chain assembly by electrostatic steering technology-immunoglobulin (FAST-Ig
Indexed as
Identifiers
42108341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.